NAPA, Calif., April 25 /PRNewswire/ -- Responding to today’s announcement about the settlement between the State of Missouri and Dey, L.P., John Kling, Senior Vice President of Legal Affairs at DEY, stated, “We welcome this resolution to the pricing litigation brought by the State of Missouri. Reaching this relatively modest settlement allows us now to put this litigation behind us and move forward with what we do best -- manufacturing and marketing high-quality pharmaceuticals for the people of Missouri and the rest of the country.”
DEY has consistently participated legally and ethically within National and various State reimbursement systems. DEY believes, as do many independent critics and government officials, that these reimbursement systems, in spite of their well-intentioned purposes, are seriously flawed. Kling noted, “The Company is settling this litigation as a pragmatic solution to avoid the costs of continuing litigation and the vagaries inherent in it.”
As part of the settlement, the State of Missouri acknowledged that the settlement did not constitute an admission of fault, liability, or unlawful conduct by DEY or its affiliates.
About Dey, L.P.
Dey, L.P. is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases and respiratory-related allergies. Since 1978, patients have benefited from DEY’s commitment to innovative and affordable health care solutions. The Web sites for DEY include http://www.dey.com, http://www.accuneb.com, http://www.curosurfusa.com, http://www.duoneb.com, http://www.epipen.com.
Media contacts: Dey, L.P. Media Line 1-800-755-5560 ext. 8363 or Harriet Ullman Feinstein Kean Healthcare 617-761-6776
Dey, L.P.
CONTACT: Harriet Ullman of Feinstein Kean Healthcare for DEY,+1-617-761-6776
Web site: http://www.dey.com//
